2 news items
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
TPST
20 Jun 24
a stable HR since the top-line analysis 10 months earlier when the HR was 0.59.
A manageable safety profile is consistent with Phase 1 data
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
TPST
9 May 24
results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment
- Prev
- 1
- Next